Enteric neuropathy evoked by repeated cisplatin in the rat

Neurogastroenterology and Motility

Volumn 23, Issue 4, 2011, Pages 370-

  Vera, G ^a   Castillo, M ^a   Cabezos, P A ^a   Chiarlone, A ^a   Martin M I ^a   Gori, A ^b   Pasquinelli, G ^c   Barbara, G ^b   Stanghellini, V ^b   Corinaldesi, R ^b   De Giorgio, R ^b   Abalo, R ^a  

^a UNIVERSIDAD REY JUAN CARLOS   (Spain)

^b Department of Clinical Medicine and Centro Unificato di Ricerca BioMedica Applicata ^*  (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Chemotherapy; Enteric neuropathy; Gastrointestinal motility; Immunohistochemistry; Nitrergic neurons

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; CHARCOAL; CISPLATIN; NITRIC OXIDE SYNTHASE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLON; CONTROLLED STUDY; ELECTROMYOGRAPHY; ENTERIC NEUROPATHY; ENTEROPATHY; EVOKED RESPONSE; GASTROINTESTINAL TRANSIT; HISTOLOGY; ILEUM; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTESTINE FUNCTION; MALE; MOTOR PERFORMANCE; NEUROPATHY; NONHUMAN; PRIORITY JOURNAL; RAT; RECTUM;

ANIMALS; ANTINEOPLASTIC AGENTS; CALCITONIN GENE-RELATED PEPTIDE; CISPLATIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENTERIC NERVOUS SYSTEM; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MOTILITY; MALE; MYENTERIC PLEXUS; NERVOUS SYSTEM DISEASES; NEURONS; NITRIC OXIDE SYNTHASE; RATS; RATS, WISTAR;

EID: 79954843162     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2011.01674.x     Document Type: Article

References (47)

1. Di Fiore F, Van Cutsem E. Acute and long-term gastrointestinal consequences of chemotherapy. Best Pract Res Clin Gastroenterol 2009; 23: 113-24.
2. Darmani NA, Ray AP. Evidence for a re-evaluation of the neurochemical and anatomical bases of chemotherapy-induced vomiting. Chem Rev 2009; 109: 3158-99.
3. Rudd JA, Andrews PLR. Mechanism of acute and delayed nausea and vomiting induced by anticancer therapies. In: Hesketh PJ, ed. Management of Nausea and Vomiting in Cancer and Cancer Treatment. Sudbury, MA: Jones and Bartlett, 2005: 27-31.
4. Holmes AM, Rudd JA, Tattersall FD, Aziz Q, Andrews PL. Opportunities for the replacement of animals in the study of nausea and vomiting. Br J Pharmacol 2009; 157: 865-80.
5. Chebolu S, Wang Y, Ray AP, Darmani NA. Pranlukast prevents cysteinyl leukotriene-induced emesis in the least shrew (Cryptotis parva). Eur J Pharmacol 2010; 628: 195-201.
6. Andrews PLR, Rudd JA. The role of tachykinins and the tachykinin NK1 receptor in nausea and emesis. In: Ganten D, Page CP, Rosenthal W, Michel MC, Beavo JA, Busch A, Karlsson JA, eds. Handbook of Experimental Pharmacology. Berlin: Springer-Verlag, 2004: 359-40.
7. Campbell T, Draper S, Reid J, Robinson L. The management of constipation in people with advanced cancer. Int J Palliat Nurs 2001; 7: 110-9.
8. Authier N, Gillet JP, Fialip J et al. An animal model of nociceptive peripheral neuropathy following repeated cisplatin injections. Exp Neurol 2003; 182: 12-20.
9. Vera G, Chiarlone A, Cabezos PA, Pascual D, Martín MI, Abalo R. WIN 55, 212-2 prevents mechanical allodynia but not alterations in feeding behaviour induced by chronic cisplatin in the rat. Life Sci 2007; 81: 468-79.
10. Bornstein JC, Costa M, Grider JR. Enteric motor and interneuronal circuits controlling motility. Neurogastroenterol Motil 2004; 16: 34-8.
11. Cottrell GS, Roosterman D, Marvizon JC et al. Localization of calcitonin receptor-like receptor and receptor activity modifying protein 1 in enteric neurons, dorsal root ganglia, and the spinal cord of the rat. J Comp Neurol 2005; 490: 239-55.
12. Taylor GS, Bywater RA. Antagonism of non-cholinergic excitatory junction potentials in the guinea-pig ileum by a substance P analogue antagonist. Neurosci Lett 1986; 63: 23-6.
13. Holzer P, Schluet W, Maggi CA. Ascending enteric reflex contraction: roles of acetylcholine and tachykinins in relation to distension and propagation of excitation. J Pharmacol Exp Ther 1993; 264: 391-6.
14. Belai A, Burnstock G. Acrylamide-induced neuropathic changes in rat enteric nerves: similarities with effects of streptozotocin-diabetes. J Auton Nerv Syst 1996; 58: 56-62.
15. Belai A, Calcutt NA, Carrington AL et al. Enteric neuropeptides in streptozotocin-diabetic rats; effects of insulin and aldose reductase inhibition. J Auton Nerv Syst 1996; 58: 163-9.
16. Vera G, Chiarlone A, Martín MI et al. Altered feeding behaviour induced by long-term cisplatin in rats. Auton Neurosci 2006; 126-127: 81-92.
17. Cabezos PA, Vera G, Martin-Fontelles MI et al. Cisplatin-induced gastrointestinal dysmotility is aggravated after chronic administration in the rat. Comparison with pica. Neurogastroenterol Motil 2010; 22: 797-805.
18. Malik NM, Moore GB, Smith G, Liu YL, Sanger GJ, Andrews PL. Behavioural and hypothalamic molecular effects of the anti-cancer agent cisplatin in the rat: a model of chemotherapy-related malaise? Pharmacol Biochem Behav 2006; 83: 9-20.
19. O'Connor R, Eikelboom R. The effects of changes in housing on feeding and wheel running. Physiol Behav 2000; 68: 361-71.
20. Pascual D, Girón R, Alsasua A et al. New benzimidazole derivatives: selective and orally active 5-HT3 receptor antagonists. Eur J Pharmacol 2003; 462: 99-107.
21. Winston JH, Xu GY, Sarna SK. Adrenergic stimulation mediates visceral hypersensitivity to colorectal distension following heterotypic chronic stress. Gastroenterology 2010; 138: 294-304.
22. Brusberg M, Ravnefjord A, Lindgreen M, Larsson H, Lindström E, Martinez V. Oral clonidine inhibits visceral pain-related viscerosomatic and cardiovascular responses to colorectal distension in rats. Eur J Pharmacol 2008; 591: 243-51.
23. Koening JB, Martin CE, Nykamp SG et al. Use of multichannel electrointestinography for noninvasive assessment of myoelectrical activity in the cecum and large colon of horse. Am J Vet Res 2008; 69: 709-15.
24. Galeazzi F, Blennerhassett PA, Qiu B et al. Cigarette smoke aggravates experimental colitis in rats. Gastroenterology 1999; 117: 877-83.
25. Costa M, Furness JB, Gibbins IL. Chemical coding of enteric neurones. Prog Brain Res 1986; 68: 217-39.
26. Abalo R, José Rivera A, Vera G et al. M. Ileal myenteric plexus in aged guinea-pigs: loss of structure and calretinin-immunoreactive neurons. Neurogastroenterol Motil 2005; 17: 123-32.
27. Saper CB. An open letter to our readers on the use of antibodies. J Comp Neurol 2005; 493: 477-8.
28. Talley RW, O'Bryan RM, Gutterman JU et al. Clinical evaluation of toxic effects of cis-diamminedichloroplatinum (NSC-119875)-phase I clinical study. Cancer Chemother Rep 1973; 57: 465-71.
29. Von Hoff DD, Schilsky R, Reichert CM et al. Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep 1979; 63: 1527-31.
30. Bearcroft CP, Domizio P, Mourad FH et al. Cisplatin impairs fluid and electrolyte absorption in rat small intestine: a role for 5-hydroxytryptamine. Gut 1999; 44: 174-9.
31. Endo T, Hamaue N, Ihira E et al. Effects of granisetron, a 5-HT3 receptor antagonist, on 5-hydroxytryptamine (5-HT) release from the isolated ileum in a delayed-emesis rat model. Res Commun Mol Pathol Pharmacol 2002; 111: 55-68.
32. Ju C, Hamaue N, Machida T et al. Anti-inflammatory drugs ameliorate opposite enzymatic changes in ileal 5-hydroxytryptamine metabolism in the delayed phase after cisplatin administration to rats. Eur J Pharmacol 2008; 589: 281-7.
33. Cunningham D, Morgan R, Mills P et al. Functional and structural changes of the human proximal small intestine after cytotoxic therapy. J Clin Pathol 1985; 38: 265-70.
34. Malik NM, Liu YL, Cole N et al. Differential effects of dexamethasone, ondansetron and a tachykinin NK1 receptor antagonist (GR205171) on cisplatin-induced changes in behaviour, food intake, pica and gastric function in rats. Eur J Pharmacol 2007; 555: 164-73.
35. Ozaki A, Sukamoto T. Improvement of cisplatin-induced emesis and delayed gastric emptying by KB-R6933, a novel 5-HT3 receptor antagonist. Gen Pharmacol 1999; 33: 283-8.
36. Sharma SS, Gupta YK. Reversal of cisplatin-induced delay in gastric emptying in rats by ginger (Zingiber officinale). J Ethnopharmacol 1998; 62: 49-55.
37. Cabezos PA, Vera G, Castillo M et al. Radiological study of gastrointestinal motor activity after acute cisplatin in the rat. Temporal relationship with pica. Auton Neurosci 2008; 141: 54-65.
38. Badary OA, Awad AS, Sherief MA et al. In vitro and in vivo effects of ferulic acid on gastrointestinal motility: inhibition of cisplatin-induced delay in gastric emptying in rats. World J Gastroenterol 2006; 12: 5363-7.
39. Di Nardo G, Blandizzi C, Volta U et al. Molecular, pathological and therapeutic features of human enteric neuropathies. Aliment Pharmacol Ther 2008; 28: 25-42.
40. Schmidt Y, Unger JW, Bartke I et al. Effect of nerve growth factor on peptide neurons in dorsal root ganglia after taxol or cisplatin treatment and in diabetic (db/db) mice. Exp Neurol 1995; 132: 16-23.
41. Jarve RK, Aggarwal SK. Cisplatin-induced inhibition of the calcium-calmodulin complex, neuronal nitric oxide synthase activation and their role in stomach distention. Cancer Chemother Pharmacol 1997; 39: 341-8.
42. Jung M, Hotter G, Viñas JL et al. Cisplatin upregulates mitochondrial nitric oxide synthase and peroxynitrite formation to promote renal injury. Toxicol Appl Pharmacol 2009; 234: 236-46.
43. Mitsui R. Characterisation of calcitonin gene-related peptide-immunoreactive neurons in the myenteric plexus of rat colon. Cell Tissue Res 2009; 337: 37-43.
44. Verdú E, Vilches JJ, Rodríguez FJ et al. Physiological and immunohistochemical characterization of cisplatin-induced neuropathy in mice. Muscle Nerve 1999; 22: 329-40.
45. Apfel SC, Arezzo JC, Lipson L et al. Nerve growth factor prevents experimental cisplatin neuropathy. Ann Neurol 1992; 31: 76-80.
46. Spångéus A, Suhr O, El-Salhy M. Diabetic state affects the innervation of gut in an animal model of human type 1 diabetes. Histol Histopathol 2000; 15: 739-44.
47. Sjolund K, Sanden G, Hakanson R, Sundler F. Endocrine cells in human intestine: an immunocytochemical study. Gastroenterology 1983; 85: 1120-30.